Periodic Reporting for period 2 - AMPK-DIAB (A small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novelinnovative drug for the treatment of type 2 diabetes)

The objective of the project was to perform a proof-of-concept phase IIa trial in type 2 diabetic (T2D) patients and monitor metabolic and cardiovascular effects to reach the stage where interest and investment from third parties in the continued clinical development of the...